New diabetes combo shows promise in japanese study

NCT ID NCT02354235

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding canagliflozin to the existing diabetes drug teneligliptin helps Japanese adults with type 2 diabetes who still have high blood sugar. Over 24 weeks, researchers measured changes in HbA1c (a key blood sugar marker), fasting glucose, and body weight. The trial involved 138 participants and was completed to check both effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canagliflozin (a diabetes drug that helps lower blood sugar by making the kidneys remove sugar through urine)
What this could lead to: If successful, this could offer a new combination treatment option for people with type 2 diabetes who need better blood sugar control.
What could go wrong: This is a completed Phase 3 trial in a specific population (Japanese patients), so results may not apply to other groups. The study is relatively small (138 participants) and does not test long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Reserch site

Kanto, Japan
Reserch site

Kinki, Japan
Reserch site

Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.